Blood serum pyridoxal-5-phosphate, homocysteine and neopterin concentrations have been examined in 30 healthy individuals and 87 patients with coronary heart disease, verified by coronary angiography. Patients have been observed before percutaneus transluminal coronary angioplasty (31 patients with one-artery disease, 30 with two-or three-artery disease, 26 with restenosis). Results suggest that lowered serum pyridoxal-5-phosphate concentrations were an earlier indicator of coronary heart disease than increase of serum homocysteine concentration above 15 μπιοΙ/L. An increase of serum neopterin concentration appears to be a marker of coronary disease activity rather than a marker of the presence of coronary heart disease.
Introduction
Many serious illnesses and conditions that predispose persons to serious disease, such as cigarette smoking or alcohol/drug abuse, are associated with decreased blood levels of pyridoxal-5-phosphate (P-5-P) ( 1 ) . Working in cardiological wards at Paul Stradin's Clinical University Hospital of Riga we have observed many patients with P-5-P deficiency (2) . These observation has been confirmed by other investigators (3) . After the finding that homocysteine may promote growth of vascular endothelial (4) and smooth muscle cells (5) , this amino acid has been proposed as a link to atherosclerosis development and progression. Neopterin, a pteridine derivative, is secreted by macrophages after their stimulation by the cytokine interferon-? and is a sensitive marker of cell-mediated immune system activation (6, 7) . Studies have reported an association between neopterin levels and the grade of atherosclerosis (8, 9) . Nevertheless, the results of further investigations allowed to suggest that neopterin may be a marker of coronary disease activity rather than a marker of the presence of coronary artery disease ( 10) . Thus, the aim of this study was to compare the sensitivity of these 3 indexes in patients with coronary heart disease (CHD).
Materials and Methods

30
Healthy individuals and 87 patients with CHD verified by coronary angiography were examined in this study. Patient with diabetes and/or renal complications, as well as patients that received statins in their treatment, were excluded. All patients were examined before percutaneous transluminal coronary angioplasty (PTCA). In total, 31 patients with one-artery disease, 30 patients with two-or three-artery disease and 26 with restenosis have been included. Blood serum P-5-P concentrations were determined by the method of Serfontein and others (3), while serum concentrations of homocysteine (Abbot Imx, Ref. 11) and of neopterin (BRAHMS, Berlin, Germany) were measured by commercially available immunoassays according to the manufacturers' instructions. Standard deviations (S.D.), standard errors (S.E.M.) were calculated and statistical significance between the values obtained from healthy individuals (control) and the groups of CHD patients were calculated by Student's ttest. P-values below 0.05 were considered to indicate significant differences.
Results
In healthy individuals the mean ± S.D. serum concentration of P-5-P was 52. 4 ues of P-5-P in healthy individuals and in all 3 groups of CHD patients. Low P-5-P concentrations existed in all groups of CHD patients (P < 0.001), the lowest levels were identified in patients with restenosis. In all groups of CHD patients, the mean serum homocysteine concentrations were elevated (P< 0.001; Fig. 2 ), patients with two-and three-artery disease and patients with restenosis presented with mean values above 15 Limol/T,. Average serum neopterin concentrations were also increased in all groups of CHD patients ι Ρ < 0.001; Fig. 3 ), and patients with two-and threeartery disease and with restenosis had average neopterin concentrations above 8.7 nmol/L (the upper limit of serum concentration found in healthy persons). 
Discussion
Serum concentrations of P-5-P, homocysteine and neopterin in healthy individuals of this study agree with the data in literature (12) (13) (14) (15) . A decrease of serum P-5-P concentrations found in our CHD patients also agrees with the literature (13-16) . Enzyme systems, which cleave homocysteine to cysteine, are P-5-P dependent. Therefore, an increase of serum homocysteine concentrations in our CHD patients is understandable (14). Nevertheless, we observed an increase of serum homocysteine concentrations above 15 μπιοί/L only in 31.2% of our CHD patients, while a decrease of P-5-P levels was identified in 78% of cases. We suggest that it is due to the possibility of homocysteine reconversion to methionine by P-5-P independent enzyme systems (14). Thus, the lowered P-5-P values seems to be an earlier indicator of CHD than an increase of homocysteine concentrations above 15 μ mo 1/L. The data may indicate that in the pathogenesis of CHD, the loss of P-5-P becomes manifested earlier than the increase of homocysteine. Oxidative stress is considered to be primary in the events leading to CHD, and P-5-P as an aldehyde is easily oxidized under such conditions (17) as the other vitamins -5,6,7,8-tetrahydrofolate and vitamin B12 -required for the conversion of homocysteine. Thus, the data would be also in line with the view that hyperhomocysteinemia is developing as a result of the immunopathogenesis involved in CHD rather than being a primary factor in atherogenesis (18). Consequently hyperhomocysteinemia during diseases going along with persistent immunoactivation would result from an increásed demand for vitamins like folate even when dietary intake is within the recommended range.
The upper limit of serum neopterin concentrations in healthy individuals is 8.7 nmol/L (15). In this study, we have observed serum neopterin above this limit in 31% of CHD patients. The majority of these patients was in the group of two-and three-artery disease as well as in the group of restenosis, i.e. in patients with more serious illness. The data suggest that an increase of serum neopterin concentration in CHD patients may be a marker of coronary disease activity rather than a marker of the presence of CHD.
